One of the most stubborn puzzles in the biology of aging concerns a change that happens inside nearly every human body: as we grow older, our muscles become weaker and more easily fatigued, yet at the same time they quietly transform their internal composition, shifting away from the fast, powerful fibers of youth and toward slow-twitch fibers that rely most heavily on the very cellular machinery that is failing. This paradox, in which aging muscle leans harder on mitochondria precisely as those mitochondria deteriorate, has long suggested that something deeper is driving the transition. Now researchers at the University of Copenhagen report that they have identified a molecular cause of the shift, and, more provocatively, that the shift may not be a form of decline at all but a deliberate act of self-protection by the muscle. The findings, published in Nature Aging, point to a druggable nuclear receptor and a mitochondrial fat molecule as potential levers for preserving muscle function in old age.
To appreciate the significance of the discovery, it helps to understand how skeletal muscle is built. Muscle tissue is composed of bundles of fibers that come in distinct functional flavors. Fast-twitch fibers are tuned for quick, forceful bursts of effort but tire rapidly. Slow-twitch fibers are built for endurance and are packed with mitochondria, the organelles commonly described as the powerhouses of the cell. With age, muscle mitochondria work less efficiently, and yet the fiber population drifts toward the slow-twitch, mitochondria-dependent type. A similar shift occurs in many diseases that cause muscle wasting, which suggests that the phenomenon reflects a shared biological program rather than random wear and tear.
The Copenhagen-led team, working across more than 20 institutions and led by the NNF Center for Basic Metabolic Research at the University of Copenhagen together with the Center for Adipocyte Signaling at the University of Southern Denmark, focused their investigation on a fat molecule called cardiolipin. Cardiolipin occupies a singular position in cellular architecture: it is found essentially nowhere else in the cell but the inner membrane of mitochondria, where it is essential for maintaining that membrane’s characteristic folded structure, the cristae that give mitochondria their enormous effective surface area. Without adequate cardiolipin, mitochondria cannot produce sufficient energy, nor can they generate the metabolic signals and molecular building blocks that cells depend on to function.
When the researchers measured cardiolipin in muscle mitochondria from mice and humans, they found a consistent pattern: levels decline with both age and disease, and the mitochondria in cardiolipin-poor muscle appear distorted and unable to operate properly. That correlation alone, however, could not settle the question of causation. Declining cardiolipin might simply be a consequence of aging rather than a driver of the changes that accompany it. To distinguish between these possibilities, the team performed a decisive experiment in young mice, artificially lowering cardiolipin levels to mimic the drop seen naturally in aging. The result was striking: the young animals developed the same fast-to-slow-twitch fiber shift that occurs in aged mice and in aging humans, indicating that cardiolipin loss is sufficient to trigger the remodeling program on its own.
Even more consequential was what happened when the researchers partially restored cardiolipin. Bringing levels back to roughly two-thirds of normal was enough to begin reversing muscle wasting in the animals and to prevent their early deaths entirely. This partial-rescue result carries substantial therapeutic weight, because it suggests that a treatment does not need to fully normalize cardiolipin to deliver meaningful benefit. Senior author Zachary Gerhart-Hines, Associate Professor at the NNF Center for Basic Metabolic Research at the University of Copenhagen, emphasized this point in the announcement of the work, noting that even a partial recovery of cardiolipin was enough to bring the muscle back, and that the central question now is whether cardiolipin can be increased in aging muscle or whether the downstream pathway can be targeted to promote healthy adaptations.
But why would a muscle respond to mitochondrial damage by remodeling itself into a slower, more mitochondria-dependent fiber type? The answer the researchers uncovered reframes the entire phenomenon as a defense mechanism. As cardiolipin levels fall, the strained mitochondria generate far more reactive oxygen species, or ROS, the chemically reactive molecules that damage cellular components in excess. Yet ROS is not merely a destructive byproduct; it also functions as a signal. When the team used an antioxidant to mop up ROS in cardiolipin-depleted muscle cells, the shift toward slow-twitch fibers was blunted, demonstrating that the ROS signal is what initiates the remodeling program rather than an incidental side effect of it.
Tracing that signal to its destination, the researchers identified a protein called ERRγ, a nuclear receptor that acts as the switch driving the fiber-type transformation. ERRγ triggers muscle cells to remodel their mitochondria and convert from fast-twitch to slow-twitch identity. The causal role of the receptor was confirmed in the opposite direction: when the scientists blocked ERRγ in cultured muscle cells, the fiber switch was completely shut down. In other words, the entire adaptive program, from ROS sensing to mitochondrial remodeling to fiber-type conversion, runs through this single regulatory node, making it an unusually clean target for intervention.
The logic of the adaptation becomes clearer when one follows what the remodeled fibers do with sugar. Cardiolipin-deficient mice pulled much more glucose out of the bloodstream than expected, but not to burn it for energy. By tracing labeled sugar through the muscle, the researchers showed that the glucose was instead diverted into the manufacture of the cell’s own antioxidants, molecules that neutralize ROS and shield the stressed cell from further oxidative damage. The slow-twitch state, in this reading, is a metabolic bargain: the muscle trades raw power for biochemical protection. Fabian Finger, Assistant Professor at the University of Copenhagen and first and co-corresponding author of the study, described the switch as the muscle trading power for protection rather than failing, and cautioned that interfering with it can backfire. In a telling result, mice given antioxidants to clear ROS fared worse, not better, because the treatment suppressed a protective response the animals needed.
The translational implications are unusually concrete for basic mitochondrial biology. Cardiolipin is already a pharmacological target: the FDA recently granted accelerated approval to elamipretide, a drug proposed to stabilize cardiolipin, for the rare genetic disorder Barth syndrome. Whether that class of compounds can be repurposed or adapted for age-related muscle decline remains an open question, but the existence of an approved pathway demonstrates that the target is druggable. ERRγ offers a second point of entry. It belongs to the nuclear receptor family, a class of molecules targeted by roughly 10 to 15 percent of all FDA-approved small-molecule medications, and activators of ERRγ are already in preclinical development for other indications. The study was funded by the Novo Nordisk Foundation, the European Research Council, the Lundbeck Foundation and the US National Institutes of Health, among others, and the published work carries a disclosure that senior author Zachary Gerhart-Hines works in some capacity for Embark Laboratories ApS, a company developing therapeutics for diabetes and obesity.
Important caveats remain. The causal experiments were carried out in mice, and the human samples served only to confirm that cardiolipin also declines with age in people; whether the same ROS-driven, ERRγ-mediated switch operates identically in human muscle has yet to be demonstrated directly. Nor is it yet known whether raising cardiolipin in aging human muscle, or modulating ERRγ activity, would improve function without unintended metabolic consequences, particularly given the finding that blocking the pathway entirely shuts down what appears to be a protective program. Still, the study resolves a genuine paradox with a coherent mechanism: the fast-to-slow-twitch shift of aging is not the muscle surrendering to decay but a regulated trade of performance for resilience, governed by a lipid whose loss destabilizes mitochondria and a receptor that reorganizes the cell in response. If future work can safely tilt that trade back toward function, the hidden switch behind aging muscle may become one of the first points of genuine therapeutic control over a process long accepted as inevitable.
Subject of Research: The role of the mitochondrial lipid cardiolipin and the nuclear receptor ERRγ in driving age-related muscle fiber-type switching
Article Title: The hidden switch behind one of the biggest paradoxes in aging muscle
Article References: The hidden switch behind one of the biggest paradoxes in aging muscle. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: aging, muscle, mitochondria, cardiolipin, ERRγ, reactive oxygen species, muscle fibers, nuclear receptors, elamipretide, Nature Aging, sarcopenia, University of Copenhagen
